FDA Chief Counsel Bradshaw Brings DoJ Experience
This article was originally published in The Tan Sheet
Executive Summary
Former Department of Justice attorney Sheldon Bradshaw will serve as the new FDA Chief Counsel
You may also be interested in...
Once and future Chief Counsel
Gerald Masoudi returns from the Justice Department to become FDA chief counsel/associate general counsel effective Oct. 12. He replaces Sheldon Bradshaw, who left the agency Sept. 12 to join the Washington, D.C. firm Hunton & Williams (1"The Tan Sheet" Sept. 10, 2007, In Brief). The role will be a familiar one for Masoudi, who came to FDA in 2004 as deputy chief counsel and was acting chief counsel for several months before Bradshaw was named to the post (2"The Tan Sheet" April 11, 2005, p. 7). Since 2005, Masoudi has been deputy assistant attorney general in charge of International, Policy and Appellate Matters in the Antitrust Division at the U.S. Department of Justice. Before joining FDA, Masoudi was a partner at Kirkland & Ellis, where his background included antitrust work (3"The Tan Sheet" Nov. 15, 2004, p. 12)...
Chief counsel leaves FDA
Sheldon Bradshaw, chief counsel of FDA, resigned from the agency Sept. 6 to join Hunton & Williams' food and drug law practice, according to the firm. A former Justice Department attorney, Bradshaw served as top lawyer at FDA since 2005, replacing Dan Troy (1"The Tan Sheet" April 11, 2005, p. 7). During his tenure, he reviewed and approved regulations and guidance including a proposed rule clarifying information included in new dietary ingredient notifications and a draft guidance on the kind of scientific data the FDA's Center for Food Safety and Applied Nutrition would find useful in new dietary ingredient submissions. Deputy Chief Counsel Jeffrey Senger will serve as acting chief until a permanent replacement is found, according to FDA staffers in the Office of Chief Counsel...
Meet Masoudi: Deputy Counsel Brings Antitrust Experience To FDA
FDA Deputy Chief Counsel Gerald Masoudi can be expected to reinforce the agency's aggressive stance toward product liability suits that encroach on its regulatory authority